With box warnings

Without box warnings

Branded

Generic

5 results

inlyta
(axitinib)
U.S. Pharmaceuticals
Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.
pazopanib
(pazopanib hydrochloride)
Novugen Pharma (USA) LLC.
Usage: Pazopanib tablets are indicated for adults with advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. Efficacy for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.
pazopanib
(Pazopanib)
SUN PHARMACEUTICAL INDUSTRIES, INC.
Usage: Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Efficacy has not been established for adipocytic STS or gastrointestinal stromal tumors.
sorafenib
(Sorafenib)
Teva Pharmaceuticals Inc
Usage: Sorafenib tablets are indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
temsirolimus
(temsirolimus)
Accord Healthcare Inc.
Usage: Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.

Medications for Carcinoma Renal Cell

inlyta